Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR‐ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR‐ABL substrate and is associated with proliferation, migration, tumorigenesis and chemoresistance in several cancers. Furthermore, LASP1 was shown to bind to the chemokine receptor 4 (CXCR4), thought to be involved in mechanisms of relapse. In order to identify potential LASP1‐mediated pathways and related factors that may help to further eradicate minimal residual disease (MRD), the effect of LASP1 on processes involved in progression and maintenance of CML was investigated. The present data indicate that not ...
Summary: Chronic myeloid leukemia (CML) is propagated by leukemia stem cells (LSCs) that are not era...
Chronic myeloid leukaemia (CML) is characterised by the presence of the fusion protein BCR-ABL1. The...
Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML),...
Chronic myeloid leukemia (CML) is characterized by a genomic translocation generating a permanently ...
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4),...
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4),...
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor4 (CXCR4), ...
Das Verständnis der molekularen Mechanismen, die einer malignen Erkrankung zugrunde liegen, ist der ...
, and is thought to be due to enhanced survival signaling responses to environmental factors that pr...
Abstract Background LASP2 (LIM and SH3 Protein 2) is a small focal adhesion protein belongs to nebul...
The kinase activity of BCR-ABL1 is central to chronic myeloid leukaemia (CML) pathology. Clinical tr...
International audienceAbstract Mouse models of chronic myeloid malignancies suggest that targeting m...
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the haemopoietic stem ce...
Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leu...
Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leu...
Summary: Chronic myeloid leukemia (CML) is propagated by leukemia stem cells (LSCs) that are not era...
Chronic myeloid leukaemia (CML) is characterised by the presence of the fusion protein BCR-ABL1. The...
Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML),...
Chronic myeloid leukemia (CML) is characterized by a genomic translocation generating a permanently ...
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4),...
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4),...
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor4 (CXCR4), ...
Das Verständnis der molekularen Mechanismen, die einer malignen Erkrankung zugrunde liegen, ist der ...
, and is thought to be due to enhanced survival signaling responses to environmental factors that pr...
Abstract Background LASP2 (LIM and SH3 Protein 2) is a small focal adhesion protein belongs to nebul...
The kinase activity of BCR-ABL1 is central to chronic myeloid leukaemia (CML) pathology. Clinical tr...
International audienceAbstract Mouse models of chronic myeloid malignancies suggest that targeting m...
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the haemopoietic stem ce...
Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leu...
Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leu...
Summary: Chronic myeloid leukemia (CML) is propagated by leukemia stem cells (LSCs) that are not era...
Chronic myeloid leukaemia (CML) is characterised by the presence of the fusion protein BCR-ABL1. The...
Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML),...